Equitable Trust Co. lessened its stake in shares of Celgene Co. (NASDAQ:CELG) by 12.0% during the 3rd quarter, HoldingsChannel reports. The fund owned 5,860 shares of the biopharmaceutical company’s stock after selling 800 shares during the period. Equitable Trust Co.’s holdings in Celgene were worth $524,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ayalon Holdings Ltd. bought a new stake in Celgene during the 2nd quarter valued at $100,000. Atlantic Trust LLC bought a new stake in Celgene during the 2nd quarter valued at $101,000. Moneta Group Investment Advisors LLC boosted its position in Celgene by 2,688.6% during the 2nd quarter. Moneta Group Investment Advisors LLC now owns 10,290 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 9,921 shares in the last quarter. Harvest Fund Management Co. Ltd bought a new stake in Celgene during the 3rd quarter valued at $132,000. Finally, City Holding Co. bought a new stake in Celgene during the 2nd quarter valued at $143,000. 72.86% of the stock is currently owned by institutional investors and hedge funds.
Celgene stock opened at $66.63 on Wednesday. The company has a quick ratio of 1.99, a current ratio of 2.13 and a debt-to-equity ratio of 4.06. The firm has a market capitalization of $47.64 billion, a PE ratio of 9.74, a price-to-earnings-growth ratio of 0.42 and a beta of 1.50. Celgene Co. has a 1-year low of $65.76 and a 1-year high of $109.98.
CELG has been the topic of several recent research reports. Zacks Investment Research cut Celgene from a “buy” rating to a “hold” rating in a research report on Wednesday, September 26th. Mizuho set a $117.00 target price on Celgene and gave the company a “buy” rating in a research report on Tuesday, October 30th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Celgene in a research report on Thursday, October 11th. UBS Group set a $94.00 target price on Celgene and gave the company a “buy” rating in a research report on Saturday, October 27th. Finally, Leerink Swann set a $112.00 target price on Celgene and gave the company a “hold” rating in a research report on Friday, October 26th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and a consensus target price of $115.39.
Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers.
See Also: How analysts view the yield curve
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.